Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pyridoxine Hydrochloride

FDA-approved product (injectable, injection), marketed as Hexa-Betalin, Pyridoxine Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Pyridoxine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anemia
  • Anemia (phenotype)
  • Chronic kidney disease
  • Folate deficiency
  • Iron deficiency anemia
  • Nausea and vomiting
  • Osteoporosis
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other plain vitamin preparations
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Pyridoxine Hydrochloride, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA27.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli23.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis14.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pyridoxine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pyridoxine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV

    NCT01601626 · start 2013-07-13

    Registered record
    Registry ID
    NCT01601626
    Conditions
    HIV Infection; Tuberculosis
    Interventions
    Standard-dose Lopinavir/Ritonavir; Double-dose Lopinavir/Ritonavir; Raltegravir; Isoniazid; Pyridoxine; Pyrazinamide; Ethambutol; Rifabutin; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-07-13
    Completion
    2017-06-28
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; Tuberculosis
    InterventionStandard-dose Lopinavir/Ritonavir; Double-dose Lopinavir/Ritonavir; Raltegravir; Isoniazid +5 more
    PhasePhase 2
    Registry statusTerminated

  • Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy

    NCT01825031 · start 2013-06

    Registered record
    Registry ID
    NCT01825031
    Conditions
    Human Immunodeficiency Virus
    Interventions
    Raltegravir; Fluconazole; Azithromycin; Albendazole; Isoniazid; Ready to Use Supplementary Food
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-06
    Completion
    2016-03
    Enrolment
    1,805

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus
    InterventionRaltegravir; Fluconazole; Azithromycin; Albendazole +2 more
    PhasePhase 3
    Registry statusCompleted

  • Neurodevelopmental Outcome of Early Dietary Lysine Restriction in Pyridoxine Dependent Epilepsy Patients

    NCT01795170 · start 2013-04

    Registered record
    Registry ID
    NCT01795170
    Conditions
    Pyridoxine Dependant Epilepsy
    Interventions
    Lysine Restricted Diet; Pyridoxine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2013-04
    Completion
    2016-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPyridoxine Dependant Epilepsy
    InterventionLysine Restricted Diet; Pyridoxine
    PhaseNot recorded
    Registry statusWithdrawn

  • Trace Element Replenishment Study in Hemodialysis Patients

    NCT01473914 · start 2012-11

    Registered record
    Registry ID
    NCT01473914
    Conditions
    End Stage Renal Disease
    Interventions
    Low dose: supplemental zinc, selenium and vitamin E; Standard renal vitamin: B and C renal vitamin; Medium dose: supplemental zinc, selenium and vitamin E
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-01
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd Stage Renal Disease
    InterventionLow dose: supplemental zinc, selenium and vitamin E; Standard renal vitamin: B and C renal vitamin; Medium dose: supplemental zinc, selenium and vitamin E
    PhasePhase 3
    Registry statusCompleted

  • Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

    NCT01404312 · start 2012-05-23

    Registered record
    Registry ID
    NCT01404312
    Conditions
    Tuberculosis; HIV Infections
    Interventions
    Rifapentine (RPT); Isoniazid (INH); Pyridoxine (Vitamin B6)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05-23
    Completion
    2017-11-14
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; HIV Infections
    InterventionRifapentine (RPT); Isoniazid (INH); Pyridoxine (Vitamin B6)
    PhasePhase 3
    Registry statusCompleted

  • Feasibility and Effectiveness of Micronutrients as Palliative Care Therapy in Patients With Congestive Heart Failure

    NCT01474486 · start 2010-04

    Registered record
    Registry ID
    NCT01474486
    Conditions
    Congestive Heart Failure; Ischemic Cardiomyopathy
    Interventions
    Micronutrients
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-04
    Completion
    2016-02
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongestive Heart Failure; Ischemic Cardiomyopathy
    InterventionMicronutrients
    PhaseNot applicable
    Registry statusCompleted

  • Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis

    NCT00728507 · start 2009-11

    Registered record
    Registry ID
    NCT00728507
    Conditions
    Tuberculosis
    Interventions
    Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid; Isoniazid, Rifampin, Pyrazinamide, Ethambutol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-11
    Completion
    2013-04
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine, Moxifloxacin, Pyrazinamide, Isoniazid; Isoniazid, Rifampin, Pyrazinamide, Ethambutol
    PhasePhase 2
    Registry statusTerminated

  • The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy

    NCT00614445 · start 2008-01

    Registered record
    Registry ID
    NCT00614445
    Conditions
    Nausea and Vomiting of Pregnancy
    Interventions
    doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-01
    Completion
    2009-12
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea and Vomiting of Pregnancy
    Interventiondoxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss

    NCT00400387 · start 2006-11

    Registered record
    Registry ID
    NCT00400387
    Conditions
    Abortion, Habitual
    Interventions
    Fragmin P Forte (dalteparin sodium); Multivitamin supplement
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-11
    Completion
    2013-04
    Enrolment
    449

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAbortion, Habitual
    InterventionFragmin P Forte (dalteparin sodium); Multivitamin supplement
    PhasePhase 3
    Registry statusCompleted

  • Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer

    NCT00559858 · start 2004-12

    Registered record
    Registry ID
    NCT00559858
    Conditions
    Breast Cancer; Colorectal Cancer; Palmar-plantar Erythrodysesthesia
    Interventions
    pyridoxine hydrochloride; placebo; quality-of-life assessment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2004-12
    Completion
    Not recorded
    Enrolment
    270

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Colorectal Cancer; Palmar-plantar Erythrodysesthesia
    Interventionpyridoxine hydrochloride; placebo; quality-of-life assessment
    PhasePhase 3
    Registry statusUnknown

  • Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana

    NCT00164281 · start 2004-11

    Registered record
    Registry ID
    NCT00164281
    Conditions
    Tuberculosis; HIV Infections
    Interventions
    Isoniazid
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-11
    Completion
    2011-05
    Enrolment
    1,995

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; HIV Infections
    InterventionIsoniazid
    PhasePhase 4
    Registry statusCompleted

  • Plasma Vitamin and Homocysteine Levels and Thrombosis in Patients With Ph-negative MPNs

    NCT01878916 · start 2003-01

    Registered record
    Registry ID
    NCT01878916
    Conditions
    Thrombosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-01
    Completion
    2004-06
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombosis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)

    NCT00064753 · start 2002-05

    Registered record
    Registry ID
    NCT00064753
    Conditions
    Chronic Kidney Disease; Cardiovascular Disease; Death
    Interventions
    High Dose Multivitamin; Low Dose Multivitamin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2002-05
    Completion
    2011-10
    Enrolment
    4,110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease; Cardiovascular Disease; Death
    InterventionHigh Dose Multivitamin; Low Dose Multivitamin
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Homocysteine Study (HOST)

    NCT00032435 · start 2001-05

    Registered record
    Registry ID
    NCT00032435
    Conditions
    End Stage Renal Disease; Renal Failure
    Interventions
    PAL-40 Active; PAL-40 Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-05
    Completion
    2006-09
    Enrolment
    2,003

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd Stage Renal Disease; Renal Failure
    InterventionPAL-40 Active; PAL-40 Placebo
    PhasePhase 3
    Registry statusCompleted

  • VITRO-Trial. B Vitamins and the Secondary Prevention of Venous Thrombosis

    NCT00314990 · start 1996-01

    Registered record
    Registry ID
    NCT00314990
    Conditions
    Deep-Vein Thrombosis; Pulmonary Embolism
    Interventions
    5 mg folic acid, 50 mg pyridoxine and 0.4 mg cyanocobalamin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1996-01
    Completion
    2003-01
    Enrolment
    620

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDeep-Vein Thrombosis; Pulmonary Embolism
    Intervention5 mg folic acid, 50 mg pyridoxine and 0.4 mg cyanocobalamin
    PhaseNot applicable
    Registry statusCompleted